Foundations of Cancer Therapeutics (FCT) August 14-18, 2023
Merck lectures facilitated by Zhiaqiang An
| Mon, August 14 | Tues, August 15 | Wed, August 16 | Thurs, August 17 | Fri, August 18 |
| 9:00 Welcome & Introductions CTTP Leadership 9:05 Future of Cancer Therapeutics Development Phil Jones, MD Anderson Institute for Applied Cancer Science (IACS) 9:40 Course Introduction Zhiqiang An, UTHealth 10:00 Part 1 – How New Drugs are Discovered Target Identification Target Validation | 10:00 Part 2 – Preclinical Studies Formulation activities Drug Metabolism and Pharmakokinetics Nonclinical Safety Assessment | 10:00 Part 3 – Testing Individual Drugs in Humans Clinical Development Plan Phase I Trials Phase II Trials | 9:00 Radiation Therapy Ahsan Farooqi, MD Anderson 10:00 Part 4 – Regulatory Review Process Who Regulates? Drug Labeling Global Regulatory Strategy | 9:00 Part 6 – Diversity and Patient Engagement in Clinical Trials Importance of Patient Diversity in Clinical Trials Patient Engagement in Clinical Trials 11:00 From Bench to Biotech: (Misad)Ventures of a reformed scientist Sarah Hein, March Biosciences 11:45 Cancer Drug Development Core Introductions |
| 12-1:30 Lunch & Discussion | 12-12:45 Lunch & Discussion | 12-1:30 Lunch & Discussion | 12-1:30 Lunch & Discussion | 12-1:30 Lunch & Wrap up |
| 1:30 Part 1 (cont.) Lead Identification Lead Optimization Biologics 3:00 Overview of Cancer Therapetuics Peter Davies, Texas A&M IBT 3:30 Overview of Cancer Therapeutics Cores Suzanne Tomlinson, GCC | 12:45 Small molecule drugs Jin Wang, Baylor College of Medicine 1:30 Part 2 (cont.) Case study: Antibody Drug Development Zhiqiang An, UTHealth 3:00 Antibody Drug Conjugates to Treat Cancer Zhiqiang An, UTHealth | 1:30 Part 3 (cont) Phase III Trials 2:30 Peptides and PROTACS Wenshe Liu, Texas A&M 3:00 Cancer Prevention Strategies Praveen Rajendran, Texas A&M IBT 3:30 Cell Therapy and CAR T-cells Cliona Rooney, Baylor College of Medicine | 1:30 (Part 4 cont.) New Drug Application FDA review and Approval Process Part 5 Postmarketing Studies & Safety Surveillance Phases 3b and 4 Post Market Regulatory Activities |

